• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Screening of Ras inhibitors for clinical application in primary cholangitis

Research Project

Project/Area Number 18K15827
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 53010:Gastroenterology-related
Research InstitutionChiba University

Principal Investigator

Nakagawa Ryo  千葉大学, 大学院医学研究院, 特任講師 (60594596)

Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
KeywordsT細胞 / N-Ras / 免疫制御 / CD4+T細胞 / N-Ras阻害剤 / 原発性胆汁性胆管炎 / Ras阻害剤 / スクリーニング / 原発泳胆汁性肝硬変 / IFN-γ
Outline of Final Research Achievements

We have been analyzing the immunokinetics of primary biliary cholangitis (PBC) using molecular biological techniques. We have shown that PBC is associated with increased T cell activation and Th1 cytokine production, mainly IFN-γ, accompanied by increased N-Ras expression. And it was shown that N-Ras could be an immunoregulatory molecule for PBCs. However, the universality and specificity of the pathological relationship between PBC and N-Ras expression have not been fully analyzed. Therefore, we confirmed the reproducibility of N-Ras expression in PBCs. In addition, we compared the inhibitory effect of Ras inhibitors on Th1 cytokine production in order to select candidate drugs for the treatment of PBC. This study clarified a part of the pathogenesis of PBC and established the basis for a new therapeutic approach.

Academic Significance and Societal Importance of the Research Achievements

難病であるPBCの病態の一端を解明し、それに基づいた新たな治療法を提唱した。PBCは自己免疫性疾患にも胆汁うっ滞を改善させるための治療しか存在しない。本研究によりTas阻害剤を用いることでPBCの免疫治療が開発できる可能性を示す事ができた。これにより従来の治療法に抵抗性を示す症例に対して、治療アプローチをすることが可能となる。また、免疫動態を正常化させることで、PBCを寛解させる事ができる可能性もある。そのため、本研究の社会的意義は大きいと考える。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (5 results)

All 2021 2019 2018 Other

All Int'l Joint Research (1 results) Journal Article (1 results) (of which Peer Reviewed: 1 results) Presentation (3 results)

  • [Int'l Joint Research] The University Medical Center/Hamburg Eppendorf(ドイツ)

    • Related Report
      2020 Annual Research Report
  • [Journal Article] CD4+ T cells from patients with primary biliary cholangitis show T cell activation and differentially expressed T-cell receptor repertoires2019

    • Author(s)
      Nakagawa Ryo、Muroyama Ryosuke、Saeki Chisato、Oikawa Tsunekazu、Kaise Yoshimi、Koike Kazuhiko、Arai Jun、Nakano Masanori、Matsubara Yasuo、Takano Keiko、Hirata Yoshihiro、Saruta Masayuki、Zeniya Mikio、Kato Naoya
    • Journal Title

      Hepatology Research

      Volume: なし Issue: 6 Pages: 653-662

    • DOI

      10.1111/hepr.13318

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Presentation] N-Rasを標的としたPBC治療法の開発2021

    • Author(s)
      中川良
    • Organizer
      第107回日本消化器病学会総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] CD4 陽性T細胞を標的としたRas阻害剤による原発性胆汁性胆管炎の新規治療法開発2018

    • Author(s)
      中川良、銭谷幹男、加藤直也
    • Organizer
      第104回日本消化器病学会総会
    • Related Report
      2018 Research-status Report
  • [Presentation] 原発性胆汁性胆管炎の Ras 阻害剤によるIFN-γ 抑制療法の開発2018

    • Author(s)
      中川良、銭谷幹男、加藤直也
    • Organizer
      第54回肝臓学会総会
    • Related Report
      2018 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi